Analyst Adjustment Adds Pressure to BioNTech Shares
Veröffentlicht: 11.10.2025 um 17:00 Uhr, Redaktion boerse-global.de
Investors in BioNTech are facing renewed uncertainty as Morgan Stanley revises its outlook for the biotechnology firm. The prominent investment bank has adjusted its price target downward for the German pharmaceutical pioneer just ahead of third-quarter earnings announcements. While maintaining a positive overall rating, this recalibration arrives during an already challenging market period that could amplify existing downward momentum.
Morgan Stanley’s research team, led by analyst Terence Flynn, has decreased their price projection from $133 to $131 per share. Despite this modest reduction, the institution continues to recommend an “Overweight” position on BioNTech stock, indicating sustained confidence in the investment’s potential. The adjustment follows comprehensive reviews of valuation methodologies and emerging data patterns within the sector.
The timing... Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
